...
search icon
hrtx-img

Heron Therapeuti, Common Stock

HRTX

NAQ

$1.78

+$0.13

(7.88%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$270.73M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.15M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.81
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.04 L
$3.93 H
$1.78

About Heron Therapeuti, Common Stock

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameHRTXSectorS&P500
1-Week Return2.3%-0.03%1.53%
1-Month Return21.09%4.56%4.75%
3-Month Return43.55%1.29%2.77%
6-Month Return-4.3%-3.54%12.18%
1-Year Return-34.56%1.59%22.34%
3-Year Return-79.11%13.55%38.91%
5-Year Return-91.52%40.85%80.7%
10-Year Return-82.93%105.52%190.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue145.97M88.64M86.35M107.67M127.04M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":60.72,"profit":true},{"date":"2021-12-31","value":59.15,"profit":true},{"date":"2022-12-31","value":73.76,"profit":true},{"date":"2023-12-31","value":87.04,"profit":true}]
Cost of Revenue61.62M36.19M46.02M54.87M65.11M[{"date":"2019-12-31","value":94.65,"profit":true},{"date":"2020-12-31","value":55.59,"profit":true},{"date":"2021-12-31","value":70.69,"profit":true},{"date":"2022-12-31","value":84.29,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit84.35M52.45M40.33M52.80M61.94M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":62.18,"profit":true},{"date":"2021-12-31","value":47.81,"profit":true},{"date":"2022-12-31","value":62.59,"profit":true},{"date":"2023-12-31","value":73.43,"profit":true}]
Gross Margin57.79%59.17%46.70%49.04%48.75%[{"date":"2019-12-31","value":97.66,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":78.93,"profit":true},{"date":"2022-12-31","value":82.87,"profit":true},{"date":"2023-12-31","value":82.39,"profit":true}]
Operating Expenses295.04M280.61M258.15M227.46M172.55M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":95.11,"profit":true},{"date":"2021-12-31","value":87.5,"profit":true},{"date":"2022-12-31","value":77.09,"profit":true},{"date":"2023-12-31","value":58.48,"profit":true}]
Operating Income(210.69M)(228.16M)(217.83M)(174.66M)(110.61M)[{"date":"2019-12-31","value":-21069400000,"profit":false},{"date":"2020-12-31","value":-22816300000,"profit":false},{"date":"2021-12-31","value":-21782800000,"profit":false},{"date":"2022-12-31","value":-17465800000,"profit":false},{"date":"2023-12-31","value":-11061500000,"profit":false}]
Total Non-Operating Income/Expense11.73M2.62M(4.83M)(8.20M)(448.00K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":22.31,"profit":true},{"date":"2021-12-31","value":-41.19,"profit":false},{"date":"2022-12-31","value":-69.91,"profit":false},{"date":"2023-12-31","value":-3.82,"profit":false}]
Pre-Tax Income(204.75M)(227.28M)(220.68M)(182.02M)(110.56M)[{"date":"2019-12-31","value":-20474900000,"profit":false},{"date":"2020-12-31","value":-22727800000,"profit":false},{"date":"2021-12-31","value":-22068300000,"profit":false},{"date":"2022-12-31","value":-18202400000,"profit":false},{"date":"2023-12-31","value":-11055900000,"profit":false}]
Income Taxes1.87M(2.85M)(3.02M)(47.51M)2.73M[{"date":"2019-12-31","value":68.55,"profit":true},{"date":"2020-12-31","value":-104.24,"profit":false},{"date":"2021-12-31","value":-110.61,"profit":false},{"date":"2022-12-31","value":-1739.52,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(206.62M)(224.43M)(217.66M)(134.52M)(113.29M)[{"date":"2019-12-31","value":-20662114000,"profit":false},{"date":"2020-12-31","value":-22443100000,"profit":false},{"date":"2021-12-31","value":-21766200000,"profit":false},{"date":"2022-12-31","value":-13451600000,"profit":false},{"date":"2023-12-31","value":-11329010500,"profit":false}]
Income From Continuous Operations(204.75M)(227.28M)(220.68M)(182.02M)(119.70M)[{"date":"2019-12-31","value":-20474900000,"profit":false},{"date":"2020-12-31","value":-22727800000,"profit":false},{"date":"2021-12-31","value":-22068300000,"profit":false},{"date":"2022-12-31","value":-18202400000,"profit":false},{"date":"2023-12-31","value":-11970400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(204.75M)(224.43M)(217.66M)(134.52M)(110.56M)[{"date":"2019-12-31","value":-20474900000,"profit":false},{"date":"2020-12-31","value":-22443100000,"profit":false},{"date":"2021-12-31","value":-21766200000,"profit":false},{"date":"2022-12-31","value":-13451600000,"profit":false},{"date":"2023-12-31","value":-11055900000,"profit":false}]
EPS (Diluted)(2.50)(2.50)(2.25)(1.73)(0.86)[{"date":"2019-12-31","value":-250,"profit":false},{"date":"2020-12-31","value":-250,"profit":false},{"date":"2021-12-31","value":-225,"profit":false},{"date":"2022-12-31","value":-173,"profit":false},{"date":"2023-12-31","value":-86,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

HRTX
Cash Ratio 0.83
Current Ratio 2.28
Quick Ratio 1.74

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

HRTX
ROA (LTM) -2.31%
ROE (LTM) -2408.88%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

HRTX
Debt Ratio Lower is generally better. Negative is bad. 1.18
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.18

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

HRTX
Trailing PE NM
Forward PE NM
P/S (TTM) 1.97
P/B 12.60
Price/FCF 92
EV/R 2.60
EV/Ebitda NM
PEG NM

FAQs

What is Heron Therapeuti share price today?

Heron Therapeuti (HRTX) share price today is $1.78

Can Indians buy Heron Therapeuti shares?

Yes, Indians can buy shares of Heron Therapeuti (HRTX) on Vested. To buy Heron Therapeuti from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HRTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Heron Therapeuti be purchased?

Yes, you can purchase fractional shares of Heron Therapeuti (HRTX) via the Vested app. You can start investing in Heron Therapeuti (HRTX) with a minimum investment of $1.

How to invest in Heron Therapeuti shares from India?

You can invest in shares of Heron Therapeuti (HRTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in HRTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Heron Therapeuti shares
What is Heron Therapeuti 52-week high and low stock price?

The 52-week high price of Heron Therapeuti (HRTX) is $3.93. The 52-week low price of Heron Therapeuti (HRTX) is $1.04.

What is Heron Therapeuti price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Heron Therapeuti (HRTX) is 12.60

What is the Market Cap of Heron Therapeuti?

The market capitalization of Heron Therapeuti (HRTX) is $270.73M

What is Heron Therapeuti’s stock symbol?

The stock symbol (or ticker) of Heron Therapeuti is HRTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top